Services do NOT include
Shipment of vaccine formulations. Travel/accommodation/other costs of users who access the facility for the purposes of training etc.
Possible Output
Raw data will be provided to users in the form of cytokine concentrations measured in potency assay samples.
Sample Requirements - input of users
Users should provide vaccine formulations in sufficient quantities for testing in between 5 and 10 donor blood samples.
Lead Scientist
Dr. Steven Smith
Luminex potency assay for cytokine/chemokine responses in human blood
Free
Publications
-
Smith SG et al. Broad heparin-binding haemagglutinin-specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination. Eur J Immunol. 2012 Sep;42(9):2511-22
-
Lalor MK et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis. 2011 Oct 1;204(7):1075-85
Description of service
Luminex potency assay for cytokine/chemokine responses in human blood. LSHTM will provide a whole-blood assay to compare the potency of vaccine candidates based on their ability to induce innate and adaptive cytokine and chemokine responses, detected by capturing the signalling molecules on customised or commercial Luminex bead arrays. This will be used to confirm the potency of vaccine candidates in a human immune system model, to compare different vaccines or the same vaccine produced in different expression hosts, or to ensure consistent production quality and batch-to-batch reproducibility, including the viability of live whole cell vaccines.
Timeline
1-2 months, once vaccine formulations are received